Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

The investigators noted cardiovascular events for up to 1 year post-discharge in 18.5% of RSV patients, compared with 17.7% ...

The idea that herpes infections trigger or contribute to Alzheimer's disease has been gaining favor among some scientists, ...